EYPT vs. TXG, TRNS, ALNT, AEHR, CTKB, LAB, SENS, FEIM, MASS, and QSI
Should you be buying Eyepoint Pharmaceuticals stock or one of its competitors? The main competitors of Eyepoint Pharmaceuticals include 10x Genomics (TXG), Transcat (TRNS), Allient (ALNT), Aehr Test Systems (AEHR), Cytek Biosciences (CTKB), Standard BioTools (LAB), Senseonics (SENS), Frequency Electronics (FEIM), 908 Devices (MASS), and Quantum-Si (QSI). These companies are all part of the "measuring and control equipment" industry.
Eyepoint Pharmaceuticals vs. Its Competitors
10x Genomics (NASDAQ:TXG) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.
10x Genomics has a net margin of -13.13% compared to Eyepoint Pharmaceuticals' net margin of -337.93%. 10x Genomics' return on equity of -12.88% beat Eyepoint Pharmaceuticals' return on equity.
In the previous week, 10x Genomics had 7 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 10 mentions for 10x Genomics and 3 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.93 beat 10x Genomics' score of 0.32 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the news media.
10x Genomics has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.73, meaning that its share price is 73% more volatile than the S&P 500.
10x Genomics currently has a consensus target price of $13.54, indicating a potential upside of 2.71%. Eyepoint Pharmaceuticals has a consensus target price of $25.38, indicating a potential upside of 119.24%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than 10x Genomics.
84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 9.4% of 10x Genomics shares are owned by insiders. Comparatively, 4.5% of Eyepoint Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Eyepoint Pharmaceuticals has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
10x Genomics and Eyepoint Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get Eyepoint Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding EYPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eyepoint Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:EYPT) was last updated on 8/21/2025 by MarketBeat.com Staff
MarketBeat All Access